Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide

doi:10.19982/j.issn.1000-6621.20210511

Abstract

Abstract:

Pyrazinamide is one of the most important first-line therapeutic drugs for tuberculosis, but the resistance of Mycobacterium tuberculosis to this drug is increasing year by year. At present, molecular mechanisms and drug resistance related genes of pyrazinamide is still inconclusive. The authors review research progress of pyrazinamide resistance related genes, including pncA, rpsA, panD, fadD2 and FAS-I.

Key words: Mycobacterium tuberculosis, Pyrazinamide, Drug resistance, Genes

CLC Number:

R52
R446.5

ZHOU Ting-ting, ZHENG Xiao-man, OUYANG Jing, LU Yan-qiu, CHEN Yao-kai. Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide[J]. Chinese Journal of Antituberculosis, 2022, 44(1): 102-105. doi: 10.19982/j.issn.1000-6621.20210511

References 29

[1]	World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization, 2021.
[2]	Kempker RR, Heinrichs MT, Nikolaishvili K, et al. Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis. Antimicrob Agents Chemother, 2017, 61(6):e00226-17. doi: 10.1128/AAC.00226-17.0. doi: 10.1128/AAC.00226-17.0
[3]	Singh R, Dwivedi SP, Gaharwar US, et al. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol, 2020, 128(6):1547-1567. doi: 10.1111/jam.14478. doi: 10.1111/jam.14478 pmid: 31595643
[4]	Khan MT, Malik SI, Ali S, et al. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC Infect Dis, 2019, 19(1):116. doi: 10.1186/s12879-019-3764-2. doi: 10.1186/s12879-019-3764-2 URL
[5]	Liu W, Chen J, Shen Y, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resis-tant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect, 2018, 24(9):e1011-1016. doi: 10.1016/j.cmi.2017.12.012. doi: 10.1016/j.cmi.2017.12.012
[6]	Dudley MZ, Sheen P, Gilman RH, et al. Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection. Am J Trop Med Hyg, 2016, 95(6):1239-1246. doi: 10.4269/ajtmh.15-0711. doi: 10.4269/ajtmh.15-0711 URL
[7]	Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Commun, 2017, 8(1):588. doi: 10.1038/s41467-017-00721-2. doi: 10.1038/s41467-017-00721-2 pmid: 28928454
[8]	Li K, Yang Z, Gu J, et al. Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China. Front Microbiol, 2020, 11:594171. doi: 10.3389/fmicb.2020.594171. doi: 10.3389/fmicb.2020.594171
[9]	Ei PW, Mon AS, Htwe MM, et al. Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar. Tuberculosis (Edinb), 2020, 125:102013. doi: 10.1016/j.tube.2020.102013. doi: 10.1016/j.tube.2020.102013
[10]	Naluyange R, Mboowa G, Komakech K, et al. High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One, 2020, 15(5):e0232543. doi: 10.1371/journal.pone.0232543. doi: 10.1371/journal.pone.0232543
[11]	Wu X, Lu W, Shao Y, et al. PncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects. Infect Genet Evol, 2019, 72:147-150. doi: 10.1016/j.meegid.2018.11.012. doi: 10.1016/j.meegid.2018.11.012 URL
[12]	Katale BZ, Mbelele PM, Lema NA, et al. Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania. BMC Genomics, 2020, 21(1):174. doi: 10.1186/s12864-020-6577-1. doi: 10.1186/s12864-020-6577-1 URL
[13]	Aggarwal M, Singh A, Grover S, et al. Role of pncA gene mutations W68R and W68G in pyrazinamide resistance. J Cell Biochem, 2018, 119(3):2567-2578. doi: 10.1002/jcb.26420. doi: 10.1002/jcb.26420 pmid: 28980723
[14]	Shi J, Su R, Zheng D, et al. Pyrazinamide Resistance and Mutation Patterns Among Multidrug-Resistant Mycobacterium tuberculosis from Henan Province. Infect Drug Resist, 2020, 13:2929-2941. doi: 10.2147/IDR.S260161. doi: 10.2147/IDR.S260161 URL
[15]	Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science, 2011, 333(6049):1630-1632. doi: 10.1126/science.1208813. doi: 10.1126/science.1208813 URL
[16]	Dillon NA, Peterson ND, Feaga HA, et al. Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA. Sci Rep, 2017, 7(1):6135. doi: 10.1038/s41598-017-06415-5. doi: 10.1038/s41598-017-06415-5 URL
[17]	Vallejos-Sanchez K, Lopez JM, Antiparra R, et al. Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid. Sci Rep, 2020, 10(1):8356. doi: 10.1038/s41598-020-65173-z. doi: 10.1038/s41598-020-65173-z pmid: 32433489
[18]	Gopal P, Nartey W, Ragunathan P, et al. Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. ACS Infect Dis, 2017, 3(11):807-819. doi: 10.1021/acsinfecdis.7b00079. doi: 10.1021/acsinfecdis.7b00079 URL
[19]	Zhang S, Chen J, Shi W, et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect, 2013, 2(6):e34. doi: 10.1038/emi.2013.38. doi: 10.1038/emi.2013.38
[20]	Shi W, Chen J, Feng J, et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect, 2014, 3(8):e58. doi: 10.1038/emi.2014.61. doi: 10.1038/emi.2014.61
[21]	Gopal P, Sarathy JP, Yee M, et al. Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nat Commun, 2020, 11(1):1661. doi: 10.1038/s41467-020-15516-1. doi: 10.1038/s41467-020-15516-1 URL
[22]	Sun Q, Li X, Perez LM, et al. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nat Commun, 2020, 11(1):339. doi: 10.1038/s41467-019-14238-3. doi: 10.1038/s41467-019-14238-3 URL
[23]	Pandey B, Grover S, Tyagi C, et al. Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis. Gene, 2016, 581(1):31-42. doi: 10.1016/j.gene.2016.01.024. doi: 10.1016/j.gene.2016.01.024 URL
[24]	Rosen BC, Dillon NA, Peterson ND, et al. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2017, 61(2):e02130-16. doi: 10.1128/AAC.02130-16. doi: 10.1128/AAC.02130-16
[25]	Elad N, Baron S, Peleg Y, et al. Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3Å resolution. Nat Commun, 2018, 9(1):3886. doi: 10.1038/s41467-018-06440-6. doi: 10.1038/s41467-018-06440-6 URL
[26]	Ahmady A, Poolad T, Rafee P, et al. Study of pyrazinamidase structural changes in pyrazinamide resistant and susceptible isolates of Mycobacterium tuberculosis. Tuberk Toraks, 2013, 61(2):110-114. doi: 10.5578/tt.3888. doi: 10.5578/tt.3888 URL
[27]	Sayahi H, Pugliese KM, Zimhony O, et al. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M.tuberculosis fatty acid synthase I. Chem Biodivers, 2012, 9(11):2582-2596. doi: 10.1002/cbdv.201200291. doi: 10.1002/cbdv.201200291 URL
[28]	Werngren J, Alm E, Mansjo M. Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That? J Clin Microbiol, 2017, 55(6):1920-1927. doi: 10.1128/JCM.02532-16. doi: 10.1128/JCM.02532-16 pmid: 28404681
[29]	Tan Y, Hu Z, Zhang T, et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resis-tance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol, 2014 52(1):291-297. doi: 10.1128/JCM.01903-13. doi: 10.1128/JCM.01903-13 URL